Antipsychotic Discontinuation in High-risk Subjects
|ClinicalTrials.gov Identifier: NCT01758887|
Recruitment Status : Withdrawn (administrative reason)
First Posted : January 1, 2013
Last Update Posted : October 13, 2016
- Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control?
- What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk subjects for psychosis?
- What about the dopamine synthesis in recurred clinical high risk subjects for psychosis after the discontinuation?
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Antipsychotic Discontinuation in High-risk Subjects|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||September 2016|
|Estimated Study Completion Date :||September 2016|
clinical high risk subjects for psychosis
- Presynaptic dopamine synthesis in the striatum [ Time Frame: baseline ]measured with [18F]DOPA positron emission tomography
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01758887
|Korea, Republic of|
|Seoul National University Hospital|
|Seoul, Korea, Republic of, 110-744|
|Principal Investigator:||Jun Soo Kwon, MD PhD||Seoul National University College of Medicine|